keyword
MENU ▼
Read by QxMD icon Read
search

melanoma Stage 3

keyword
https://www.readbyqxmd.com/read/29659679/surveillance-imaging-with-fdg-pet-ct-in-the-post-operative-follow-up-of-stage-3-melanoma
#1
J Lewin, L Sayers, D Kee, I Walpole, A Sanelli, L Te Marvelde, A Herschtal, J Spillane, D Gyorki, D Speakman, V Estall, S Donahoe, M Pohl, K Pope, M Chua, S Sandhu, G A McArthur, C J McCormack, M Henderson, R J Hicks, M Shackleton
Background: As early detection of recurrent melanoma maximizes treatment options, patients usually undergo post-operative imaging surveillance, increasingly with FDG-PET/CT (PET). To assess this, we evaluated stage 3 melanoma patients who underwent prospectively applied and sub-stage-specific schedules of PET surveillance. Patients and Methods: From 2009, patients with stage 3 melanoma routinely underwent PET +/- MRI brain scans via defined schedules based on sub-stage-specific relapse probabilities...
April 12, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29659371/real-world-use-safety-and-survival-of-ipilimumab-in-metastatic-cutaneous-melanoma-in-the-netherlands
#2
Anouk Jochems, Brenda Leeneman, Margreet G Franken, Maartje G Schouwenburg, Maureen J B Aarts, Alexander C J van Akkooi, Franchette W P J van den Berkmortel, Alfonsus J M van den Eertwegh, Gerard Groenewegen, Jan Willem B de Groot, John B A G Haanen, Geke A P Hospers, Ellen Kapiteijn, Rutger H Koornstra, Wim H J Kruit, Marieke W J Louwman, Djura Piersma, Rozemarijn S van Rijn, Albert J Ten Tije, Gerard Vreugdenhil, Michel W J M Wouters, Carin A Uyl-de Groot, Koos J M van der Hoeven
Phase III trials with ipilimumab showed an improved survival in patients with metastatic melanoma. We evaluated the use and safety of ipilimumab, and the survival of all patients with metastatic cutaneous melanoma (N=807) receiving ipilimumab in real-world clinical practice in The Netherlands using data from the Dutch Melanoma Treatment Registry. Patients who were registered between July 2012 and July 2015 were included and analyzed according to their treatment status: treatment-naive (N=344) versus previously-treated (N=463)...
April 13, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29658430/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma
#3
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Michele Maio, Alfonsus J M van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marreaud, Alexander C J van Akkooi, Stefan Suciu, Caroline Robert
Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. Methods Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred...
April 15, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29655645/proton-beam-irradiation-a-safe-procedure-in-post-equatorial-extraocular-extension-from-uveal-melanoma
#4
Ira Seibel, Aline I Riechardt, Katharina Erb-Eigner, Alexander Böker, Dino Cordini, Jens Heufelder, Antonia M Joussen
PURPOSE: This study was performed to show long-term outcomes concerning metastasis rates and local recurrence rates after primary proton beam therapy in uveal melanoma with posterior extraocular extension (EOE) with the main focus on optic nerve invasion. DESIGN: Retrospective case series METHODS: All patients treated with primary proton beam therapy for choroidal or ciliary body melanoma with posterior EOE between July 1998 and August 2010 were included. EOE was either detected upon sonography at primary examination or during the surgical application of tantalum clips onto the sclera...
April 12, 2018: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29653110/sirna-mediated-lrp-lr-knock-down-reduces-cellular-viability-of-malignant-melanoma-cells-through-the-activation-of-apoptotic-caspases
#5
Thalia M Rebelo, Leila Vania, Eloise Ferreira, Stefan F T Weiss
The 37kDa/67kDa laminin receptor (LRP/LR) is over-expressed in tumour cells and has been implicated in several tumourigenic processes such as metastasis and telomerase activation, however, more importantly the focus of the present study is on the maintenance of cellular viability and the evasion of apoptosis. The aim of the study was to investigate the role of LRP/LR on the cellular viability of early (A375) and late stage (A375SM) malignant melanoma cells. Flow cytometry and western blot analysis revealed that A375SM cells contain more cell-surface and total LRP/LR levels in comparison to the A375 cells, respectively...
April 10, 2018: Experimental Cell Research
https://www.readbyqxmd.com/read/29614062/pseudotime-dynamics-in-melanoma-single-cell-transcriptomes-reveals-different-mechanisms-of-tumor-progression
#6
Henry Loeffler-Wirth, Hans Binder, Edith Willscher, Tobias Gerber, Manfred Kunz
Single-cell transcriptomics has been used for analysis of heterogeneous populations of cells during developmental processes and for analysis of tumor cell heterogeneity. More recently, analysis of pseudotime (PT) dynamics of heterogeneous cell populations has been established as a powerful concept to study developmental processes. Here we perform PT analysis of 3 melanoma short-term cultures with different genetic backgrounds to study specific and concordant properties of PT dynamics of selected cellular programs with impact on melanoma progression...
April 3, 2018: Biology
https://www.readbyqxmd.com/read/29602773/pd-l1-independent-mechanisms-control-the-resistance-of-melanoma-to-cd4-t-cell-adoptive-immunotherapy
#7
Stephen R Goding, Kyle A Wilson, Carolyn Rosinsky, Paul Andrew Antony
Immunotherapy is becoming the standard of care for melanoma. However, resistance to therapy is a major problem. Previously, we showed that tumor-specific, cytotoxic CD4+ T cells from tyrosinase-related protein 1 transgenic mice could overcome secondary resistance to recurring melanoma when anti-programmed cell death 1 ligand (PD-L1) checkpoint blockade was combined with either anti-lymphocyte-activated gene 3 (LAG-3) Abs or depletion of tumor-specific regulatory T (Treg ) cells. In this study, we show that PD-L1 expressed by the host, not B16 melanoma, plays a major role in the early stages of exhaustion or primary resistance...
March 30, 2018: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29573941/encorafenib-plus-binimetinib-versus-vemurafenib-or-encorafenib-in-patients-with-braf-mutant-melanoma-columbus-a-multicentre-open-label-randomised-phase-3-trial
#8
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion-Sileni, Caroline Dutriaux, Jan Willem B de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D Pickard, Victor Sandor, Caroline Robert, Keith T Flaherty
BACKGROUND: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600 -mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAFV600 -mutant melanoma. METHODS: COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries. Eligible patients were aged 18 years or older and had histologically confirmed locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma; a BRAFV600E or BRAFV600K mutation; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and were treatment naive or had progressed on or after previous first-line immunotherapy...
March 21, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29571968/ocular-treatment-of-choroidal-melanoma-in-relation-to-the-prevention-of-metastatic-death-a-personal-view
#9
REVIEW
Bertil Damato
About 50% of patients with choroidal melanoma develop metastatic disease, despite successful eradication of the primary tumor. Patient care is complicated by the fact that we do not know whether ocular treatment ever influences survival and if so in whom. Some authorities believe that metastatic spread is never preventable, because it has always occurred by the time the ocular tumor is detected. Others hold the view that metastatic spread can occur late, at least in some patients, in whom timely and successful treatment is life-saving...
March 20, 2018: Progress in Retinal and Eye Research
https://www.readbyqxmd.com/read/29570169/telomerase-reverse-transcriptase-promoter-mutations-and-solar-elastosis-in-cutaneous-melanoma
#10
Johanne Lade-Keller, Sakineh Yuusufi, Rikke Riber-Hansen, Torben Steiniche, Magnus Stougaard
The aims of this study were to assess the prognostic potential of solar elastosis grading and telomerase reverse transcriptase (TERT) promoter mutations (TERTp) in melanoma and to evaluate whether an association between solar elastosis and TERTp exists. Solar elastosis in the dermis was evaluated in hematoxylin and eosin-stained whole slides from 486 malignant melanomas. Pyrosequencing was used to detect TERTp in 189 samples. There was no association between solar elastosis and TERTp (P=0.3). Severe elastosis was associated with older age (P<0...
March 21, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29561296/potential-clinical-and-immunotherapeutic-utility-of-talimogene-laherparepvec-for-patients-with-melanoma-after-disease-progression-on-immune-checkpoint-inhibitors-and-braf-inhibitors
#11
Jason Chesney, Yoannis Imbert-Fernandez, Sucheta Telang, Mary Baum, Smita Ranjan, Mostafa Fraig, Nicolas Batty
Talimogene laherparepvec is a genetically modified herpes simplex virus type 1-based oncolytic immunotherapy for the local treatment of unresectable subcutaneous and nodal tumors in patients with melanoma recurrent after initial surgery. We report on two patients with melanoma who, after progression on numerous systemic therapies, derived clinical benefit from talimogene laherparepvec in an expanded-access protocol (ClinicalTrials.gov, NCT02147951). Intralesional talimogene laherparepvec (day 1, ≤4 ml 10 PFU/ml; after 3 weeks, ≤4 ml 10 PFU/ml every 2 weeks) was administered until complete response, no injectable tumors, progressive disease, or intolerance occurred...
March 21, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29542807/unscheduled-visits-of-patients-with-familial-melanoma-to-a-pigmented-lesion-clinic-evaluation-of-patients-characteristics-and-suspicious-lesions
#12
Rania Nabil, Elsemieke Plasmeijer, Remco van Doorn, Wilma Bergman, Nicole A Kukutsch
Approximately 10% of all melanomas occur in subjects with a family history of melanoma. This retrospective follow-up study investigated the characteristics of patients with familial melanoma who made unscheduled visits to our pigmented lesions clinic, and the diagnosis of excised lesions. A total of 110 out of 1,267 (9%) patients made at least one unscheduled visit between May 2011 and February 2016. Histopathology was taken from 59 patients. Thirty-four naevi, 7 melanomas and 3 basal cell carcinomas were detected...
March 15, 2018: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/29533281/a-case-of-a-malignant-cutaneous-mixed-tumor-chondroid-syringoma-of-the-scapula-treated-with-staged-margin-controlled-excision
#13
Karan Lal, Travis J Morrell, Michael Cunningham, Patrick OʼDonnell, Nikki A Levin, Kristine M Cornejo
Cutaneous mixed tumor (chondroid syringoma) is the cutaneous counterpart of pleomorphic adenoma of salivary glands, comprised of both epithelial and mesenchymal components. Malignant transformation is exceptionally rare, with only a few cases reported. We report a case of a malignant cutaneous mixed tumor in an 86-year-old white man who presented with a pink indurated plaque on his left scapula. He had a history of nonmelanoma skin cancers, a stage IB malignant melanoma of a lower extremity and Gleason 4 + 3 prostate cancer treated with brachytherapy, external beam irradiation, and bicalutamide...
March 6, 2018: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/29532857/cutaneous-melanoma-from-pathogenesis-to-therapy-review
#14
Giulia C Leonardi, Luca Falzone, Rossella Salemi, Antonino Zanghì, Demetrios A Spandidos, James A Mccubrey, Saverio Candido, Massimo Libra
In less than 10 years, melanoma treatment has been revolutionized with the approval of tyrosine kinase inhibitors and immune checkpoint inhibitors, which have been shown to have a significant impact on the prognosis of patients with melanoma. The early steps of this transformation have taken place in research laboratories. The mitogen‑activated protein kinase (MAPK) pathway, phosphoinositol‑3‑kinase (PI3K) pathway promote the development of melanoma through numerous genomic alterations on different components of these pathways...
April 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29531842/contemporary-outcomes-from-the-use-of-regular-imaging-to-detect-relapse-in-high-risk-cutaneous-melanoma
#15
Kok Haw Jonathan Lim, Lavinia Spain, Claire Barker, Alexandros Georgiou, Gerard Walls, Martin Gore, Samra Turajlic, Ruth Board, James M Larkin, Paul Lorigan
Background: Agreement on the utility of imaging follow-up in patients with high-risk melanoma is lacking. A UK consensus statement recommends a surveillance schedule of CT or positron-emission tomography-CT and MRI brain (every 6 months for 3 years, then annually in years 4 and 5) as well as clinical examination for high-risk resected Stages II and III cutaneous melanoma. Our aim was to assess patterns of relapse and whether imaging surveillance could be of clinical benefit. Patients and methods: A retrospective study of patients enrolled between July 2013 and June 2015 from three UK tertiary cancer centres followed-up according to this protocol was undertaken...
2018: ESMO Open
https://www.readbyqxmd.com/read/29531606/one-step-melanoma-surgery-for-patient-with-thick-primary-melanomas-to-break-the-rules-you-must-first-master-them
#16
Georgi Tchernev
BACKGROUND: We present to the attention of the medical, dermatological and oncosurgical community data that serves to indicate the indispensability of optimisation of the algorithm and recommendations for diagnosis and surgical treatment of cutaneous melanoma. These recommendations could be referred to different subgroups of patients in different clinical stages as well as to patients with different initial characterisation (histological morphology) of the primary tumours. One step surgery is not a myth, even more, it could prove to be one of the best solutions for some patient collectives with advanced stages of melanoma...
February 15, 2018: Open Access Macedonian Journal of Medical Sciences
https://www.readbyqxmd.com/read/29521881/combination-immunotherapies-implementing-adoptive-t-cell-transfer-for-advanced-stage-melanoma
#17
Kendra C Foley, Michael I Nishimura, Tamson V Moore
Immunotherapy is a promising method of treatment for a number of cancers. Many of the curative results have been seen specifically in advanced-stage melanoma. Despite this, single-agent therapies are only successful in a small percentage of patients, and relapse is very common. As chemotherapy is becoming a thing of the past for treatment of melanoma, the combination of cellular therapies with immunotherapies appears to be on the rise in in-vivo models and in clinical trials. These forms of therapies include tumor-infiltrating lymphocytes, T-cell receptor, or chimeric antigen receptor-modified T cells, cytokines [interleukin (IL-2), IL-15, IL-12, granulocyte-macrophage colony stimulating factor, tumor necrosis factor-α, interferon-α, interferon-γ], antibodies (αPD-1, αPD-L1, αTIM-3, αOX40, αCTLA-4, αLAG-3), dendritic cell-based vaccines, and chemokines (CXCR2)...
March 8, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29520523/type-of-second-primary-malignancy-after-achieving-complete-response-by-definitive-chemoradiation-therapy-in-patients-with-esophageal-squamous-cell-carcinoma
#18
Toshifumi Yamaguchi, Ken Kato, Kengo Nagashima, Satoru Iwasa, Yoshitaka Honma, Atsuo Takashima, Tetsuya Hamaguchi, Yoshinori Ito, Jun Itami, Narikazu Boku, Kazuhide Higuchi
BACKGROUND: While the standard treatment for stage II-III (non-T4) esophageal squamous cell carcinoma (ESCC) is neoadjuvant therapy followed by esophagectomy, definitive chemoradiation therapy (dCRT) is an option to treat ESCC patients who reject or may not tolerate surgical treatment. Second primary malignancy (SPM) is a problem for long-term survivors after achieving complete response (CR) by dCRT. METHODS: The source of the subjects in this study was the patients with stage II/III (excluding T4 disease) ESCC (UICC6th) who underwent dCRT from 2000 to 2011 at the National Cancer Center Hospital, Japan...
March 8, 2018: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29517220/coculture-of-two-developmental-stages-of-a-marine-derived-aspergillus-alliaceus-results-in-the-production-of-the-cytotoxic-bianthrone-allianthrone-a
#19
P E Mandelare, D A Adpressa, E N Kaweesa, L N Zakharov, S Loesgen
The genetically encoded, small-molecule chemical diversity of filamentous fungi is still largely unexplored and represents an attractive source for the discovery of new compounds. Here we report the production of new chlorinated bianthrones from coculture of two different developmental stages, or morphs, of a marine alga-derived Aspergillus alliaceus (teleomorph: Petromyces alliaceus) strain. The vegetative stage (asexual morph) can be separated from the morph that switched to sexual development (sclerotial morph); both produce distinct secondary metabolite patterns...
March 8, 2018: Journal of Natural Products
https://www.readbyqxmd.com/read/29516155/rituximab-as-a-therapeutic-option-for-patients-with-advanced-melanoma
#20
Julia K Winkler, Matthias Schiller, Carolin Bender, Alexander H Enk, Jessica C Hassel
Treatment of metastatic melanoma remains challenging, despite a variety of new and promising immunotherapeutic and targeted approaches to therapy. New treatment options are still needed to improve long-term tumour control. We present a case series of seven patients with metastatic melanoma who were treated individually with the anti-CD20 antibody rituximab between July 2014 and July 2015. Two of the patients were treated in an adjuvant setting. All patients had already received a variety of treatments. During an induction phase, the administration of four cycles of weekly rituximab 375 mg/m2 body surface area was planned...
March 7, 2018: Cancer Immunology, Immunotherapy: CII
keyword
keyword
62301
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"